氯替泼诺混悬眼液联合小牛血去蛋白提取物眼用凝胶治疗角膜云翳

Clinical observation of loteprednol etabonate ophthalmic suspension combined with deproteinized calf blood extract eye gel for corneal nebula

目的:观察氯替泼诺混悬眼液联合小牛血去蛋白提取物眼用凝胶治疗各类眼科炎症及外伤导致角膜云翳的临床疗效。方法:采用自身对照的方法,选择我院门诊2009-02/2010-10各类角膜疾病导致角膜云翳的97例120眼患者,在不同阶段使用氯替泼诺混悬眼液联合小牛血去蛋白提取物眼用凝胶后,对云翳消退情况进行疗效分析。结果:角膜云翳形成0～1mo内治疗24例30眼,治愈80%,有效20%。1～2mo治疗23例30眼,有效53.3%,无效46.7%;2～3mo治疗25例30眼,有效13.3%,无效86.7%;3mo以上治疗25例30眼,无效100%。结论:氯替泼诺混悬眼液联合小牛血去蛋白提取物眼用凝胶治疗各种早期角膜云翳,具有积极有效地提高视力和促进角膜恢复透明的作用。

AIM： To investigate the effect of Ioteprednol etabonate ophthalmic suspension combined with deproteinized calf blood extract eye gel in treating various kinds of ocular inflammation and corneal nebula caused by trauma. METHODS： A self-control study was performed at our hospital. Patients with corneal nebula caused by various kinds of corneal diseases from February 2009 to October 2010 were selected. The effect of Ioteprednol etabonate opthalmic suspension combined with deproeinized calf blood extract eye gel during different periods was analyzed. RESULTS： According to the development of the corneal nebula, the patients were divided into four different groups： no more than 1 month group （24 patients, 30 eyes）, 1-2 months group （23 patients, 30 eyes）, 2-3 months group （25 patients, 30 eyes） and more than 3 months group （25 patients, 30 eyes）. The cure rate of the 24 patients （30 eyes） in the no more than 1 month group was 80% and the symptom relief rate was 20% . The rate of symptom relief and the inefficiency of the 1-2 months group were 53. 3% and 46. 7% separately. And the 2-3 months group were 13.3% （the rate of symptom relief and 86.7% （the rat of inefficiency）. The inefficiency in more than 3 months group was 100%. CONCLUSION. The combination of Ioteprednol etabonate ophthalmic suspension and deproteinized calf blood extract eye gel is effective in treating various kinds of corneal nebula at the early stage and can enhance the vision as well as improve the progress of the corneal clearing restoration significantly.